Cisplatin
Who holds supplier records for Cisplatin? 12 organisations hold a current record for Cisplatin: an active US FDA Type II Drug Master File or a CEP. A further 7 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability (12 holder entries on the EDQM register, listed below). Recorded organisation countries for current records: India (5), China (2), Germany (1), United States (1) and 2 other countries (2); not recorded for 1.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Cisplatin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/cisplatin
Reading the evidence
- 12 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- 7 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (12)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Cisplatin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- HERAEUS PRECIOUS METALS GMBH AND CO KGGermanyCEP Company GMP cert on recordActive DMF 6662 · latest filing Nov 1986
- Hetero Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 28801 · latest filing Nov 2014
- Laurus Labs LimitedIndiaCEP Company GMP cert on recordActive DMF 21917 · latest filing Aug 2008
- Qilu Pharmaceutical Co., Ltd.ChinaCEP Company GMP cert on recordActive DMF 23985 · latest filing May 2010
- UMICORE ARGENTINA SACEPActive DMF 28046 · latest filing Mar 2014
- Strem Chemicals, IncUnited StatesActive DMF 7017 · latest filing Jun 1987
- VERANOVA LPUnited KingdomCEPActive DMF 9601 · latest filing Mar 1992
- IndiaCEP Company GMP cert on record
- IndiaCEP Company GMP cert on record
- ChinaCEP
- IndiaCEP Company GMP cert on record
- NetherlandsCEP
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Valid CEP holder entries (12)
Certificates of Suitability on the EDQM register for Cisplatin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 17 certificates in total, including withdrawn, expired, suspended and repeat certificates.
| Holder | Country | Certificate | Issued | EU GMP at holder's address |
|---|---|---|---|---|
| HETERO LABS LIMITED Hyderabad | IN | CEP 2026-365 - Rev 00 Cisplatin, Process-II | Sept 2026 | — |
| FRESENIUS KABI ONCOLOGY LIMITED Kalyani | IN | CEP 2025-204 - Rev 00 Cisplatin | Apr 2026 | — |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai | IN | CEP 2004-305 - Rev 04 Cisplatin | Mar 2026 | — |
| QILU PHARMACEUTICAL CO., LTD. Jinan | CN | CEP 2010-122 - Rev 03 Cisplatin | Sept 2025 | Inspected Feb 2025 Switzerland |
| UMICORE ARGENTINA S.A. Pilar | AR | CEP 2024-550 - Rev 00 Cisplatin, CISPLATIN SF | May 2025 | — |
| TAPI NL B.V. Amsterdam | NL | CEP 2000-411 - Rev 04 Cisplatin | Mar 2025 | — |
| VERANOVA, L.P. West Deptford | US | CEP 2005-253 - Rev 02 Cisplatin | Jan 2025 | — |
| LAURUS LABS LIMITED Hyderabad | IN | CEP 2012-015 - Rev 03 Cisplatin | Nov 2024 | — |
| KUNMING GUIYAN PHARMACEUTICAL CO., LTD. Kunming | CN | CEP 2009-382 - Rev 03 Cisplatin | Jun 2024 | — |
| HERAEUS PRECIOUS METALS GMBH & CO. KG Hanau | DE | CEP 2003-075 - Rev 04 Cisplatin | Oct 2023 | Inspected Oct 2025 Germany |
| CIPLA LIMITED Mumbai | IN | R1-CEP 2014-155 - Rev 00 Cisplatin | Mar 2021 | — |
| UMICORE ARGENTINA S.A. Pilar Industrial Park | AR | R1-CEP 2012-012 - Rev 00 Cisplatin | Jun 2018 | — |
The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.
Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.
Historical records (7)
Organisations whose Type II DMFs for Cisplatin are no longer active. These show a past filing, not current supply.
Show all 7 historical records
- DEGUSSA AG WERK RADEBEULInactive DMF 12012 · filed Jun 1996
- INSTITUTE DRUG TECHNOLOGY AUSTRALIA LTDInactive DMF 10898 · filed May 1994
- ANDRULIS RESEARCH CORPInactive DMF 9852 · filed Aug 1992
- TAMILNADU DADHA PHARMACEUTICALInactive DMF 7965 · filed Mar 1989
- SOCIETE FRANCAISE D'ORGANOInactive DMF 5189 · filed Dec 1983
- PLANTEX LTD CHEMICAL AND PHARMACEUTICAL WORKSInactive DMF 4824 · filed Mar 1983
- ENGELHARD MINERALS AND CHEMICAL CORPInactive DMF 4098 · filed Mar 1981
Overview
Cisplatin is a chemotherapy drug used to treat various types of cancers by interfering with the DNA replication process of cancer cells. It is one of the most potent platinum-based drugs used in the treatment of solid tumors.
Chemical identity
- IUPAC name
- azane;platinum(2+);dichloride
- Canonical SMILES
- N.N.[Cl-].[Cl-].[Pt+2]
- InChIKey
- LXZZYRPGZAFOLE-UHFFFAOYSA-L
- Synonyms
- Cis-diamminedichloroplatinum(II), cis-diamminedichloroplatinum(II), ammonia; platinum(2+), Cl2H6N2Pt, CISPLATIN [INN], CISPLATIN [JAN], CISPLATIN [MI], CISPLATIN [HSDB], CISPLATIN [IARC], CISPLATIN [USAN], CISPLATIN [MART.], CISPLATIN [USP-RS]
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Platinum-based Drug
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Cisplatin?
12 organisations hold an active US FDA Type II Drug Master File or a CEP for Cisplatin: HERAEUS PRECIOUS METALS GMBH AND CO KG (Germany), Hetero Labs Limited (India), Laurus Labs Limited (India), Qilu Pharmaceutical Co., Ltd. (China), UMICORE ARGENTINA SA, Strem Chemicals, Inc (United States), VERANOVA LP (United Kingdom) and Cipla Limited (India), and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Cisplatin Drug Master Files are active?
HERAEUS PRECIOUS METALS GMBH AND CO KG (DMF 6662), Hetero Labs Limited (DMF 28801), Laurus Labs Limited (DMF 21917), Qilu Pharmaceutical Co., Ltd. (DMF 23985), UMICORE ARGENTINA SA (DMF 28046), Strem Chemicals, Inc (DMF 7017) and VERANOVA LP (DMF 9601). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Cisplatin records mean?
7 organisations have only inactive Type II DMFs for Cisplatin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does Cisplatin have a European Certificate of Suitability?
Yes. 11 organisations hold a valid CEP for Cisplatin on the EDQM register, including HETERO LABS LIMITED Hyderabad (IN), FRESENIUS KABI ONCOLOGY LIMITED Kalyani (IN), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), QILU PHARMACEUTICAL CO., LTD. Jinan (CN), UMICORE ARGENTINA S.A. Pilar (AR) and TAPI NL B.V. Amsterdam (NL) and 6 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
How do I qualify a Cisplatin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Cisplatin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.